12610
document
Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma . BACKGROUND AND AIM Adjuvant locoregional chemotherapy has been shown to be useful to prevent recurrence after curative resection of hepatocellular carcinoma ( HCC ) in some retrospective studies . Our aim was to compare the dose effect in the prevention of tumor recurrence . METHODS A prospective randomized controlled trial was conducted in patients with curative resection of HCC ; they were given either one intra-arterial dose of cisplatin/lipiodol , or received four doses , once every 3 months . The rates of recurrence , disease-free and overall survival were compared . RESULTS During a median follow up of 818 days , 21 patients received one dose and 19 received four doses , with 10 ( 47.6 % ) and eight ( 42.1 % ) recurrences , respectively . The 1-year , 2-year and 3-year disease-free survival rates were 71 % , 54 % and 44 % for the one-dose group and 74 % , 60 % and 40 % for the four-dose group ( P = 0.78 ) . The respective overall survival rates were 85 % , 74 % , 55 % and 84 % , 71 % , 40 % ( P = 0.64 ) . The only prognostic factor was presence of vascular permeation . The side-effects were mild and tolerable . CONCLUSIONS There is no significant difference in the survival rates between the two groups . Adjuvant chemotherapy may not be useful .
12611
Intervention_Pharmacological
adjuvant chemotherapy
12612
Intervention_Surgical
curative resection
12613
Intervention_Pharmacological
Adjuvant locoregional chemotherapy
12614
Intervention_Pharmacological
cisplatin/lipiodol
12615
Intervention_Pharmacological
Adjuvant chemotherapy
12616
Outcome_Physical
rates of recurrence
12617
Outcome_Mortality
disease-free
12618
Outcome_Mortality
overall survival
12619
Outcome_Mortality
1-year , 2-year and 3-year disease-free survival rates
12620
Outcome_Mortality
overall survival rates
12621
Outcome_Physical
presence of vascular permeation
12622
Outcome_Adverse-effects
side-effects
12623
Outcome_Mortality
survival rates
12624
Participant_Condition
hepatocellular carcinoma .
12625
Participant_Condition
patients with curative resection of HCC ;
12626
Participant_Sample-size
21
12627
Participant_Sample-size
19